Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Buontempo

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Farmacia Hospitalaria : Organo Oficial De Expresion Cientifica De La Sociedad Espanola De Farmacia Hospitalaria|March 7, 2013
Coenzyme Q10 stability in pediatric liquid oral dosage formulationsP N Estévez, V Tripodi, F Buontempo, et al.
Farmacia Hospitalaria : Organo Oficial De Expresion Cientifica De La Sociedad Espanola De Farmacia Hospitalaria|June 25, 2013
Extemporaneous clobazam suspensions for paediatric use prepared from commercially available tablets and pure drugF Buontempo, M A Moretton, E Quiroga, et al.
Farmacia Hospitalaria : Organo Oficial De Expresion Cientifica De La Sociedad Espanola De Farmacia Hospitalaria|April 27, 2010
Carvedilol stability in paediatric oral liquid formulationsF Buontempo, E Bernabeu, R J Glisoni, et al.
The Journal of Nutrition, Health & Aging|September 28, 2019
Diet Modulation Restores Autophagic Flux in Damaged Skeletal Muscle CellsF M Giordano, S Burattini, F Buontempo, et al.
Current Cancer Drug Targets|December 11, 2012
Dual Inhibition of Phosphatidylinositol 3-Kinase and Mammalian Target of Rapamycin: a Therapeutic Strategy for Acute LeukemiasF Chiarini, C Evangelisti, F Buontempo, et al.
Biochemical and Biophysical Research Communications|January 13, 2004
9-Hydroxystearic acid upregulates p21(WAF1) in HT29 cancer cellsN Calonghi, C Cappadone, E Pagnotta, et al.
Leukemia|July 28, 2016
Therapeutic potential of targeting sphingosine kinases and sphingosine 1-phosphate in hematological malignanciesC Evangelisti, C Evangelisti, F Buontempo, et al.
Leukemia|September 28, 2017
Therapeutic targeting of CK2 in acute and chronic leukemiasF Buontempo, J A McCubrey, E Orsini, et al.
Leukemia|December 7, 2013
Activity of the pan-class I phosphoinositide 3-kinase inhibitor NVP-BKM120 in T-cell acute lymphoblastic leukemiaA Lonetti, I L Antunes, F Chiarini, et al.
Leukemia|November 21, 2013
Cytotoxic activity of the casein kinase 2 inhibitor CX-4945 against T-cell acute lymphoblastic leukemia: targeting the unfolded protein response signalingF Buontempo, E Orsini, L R Martins, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Farmacia Hospitalaria : Organo Oficial De Expresion Cientifica De La Sociedad Espanola De Farmacia Hospitalaria|March 7, 2013
Coenzyme Q10 stability in pediatric liquid oral dosage formulationsP N Estévez, V Tripodi, F Buontempo, et al.
Farmacia Hospitalaria : Organo Oficial De Expresion Cientifica De La Sociedad Espanola De Farmacia Hospitalaria|June 25, 2013
Extemporaneous clobazam suspensions for paediatric use prepared from commercially available tablets and pure drugF Buontempo, M A Moretton, E Quiroga, et al.
Farmacia Hospitalaria : Organo Oficial De Expresion Cientifica De La Sociedad Espanola De Farmacia Hospitalaria|April 27, 2010
Carvedilol stability in paediatric oral liquid formulationsF Buontempo, E Bernabeu, R J Glisoni, et al.
The Journal of Nutrition, Health & Aging|September 28, 2019
Diet Modulation Restores Autophagic Flux in Damaged Skeletal Muscle CellsF M Giordano, S Burattini, F Buontempo, et al.
Current Cancer Drug Targets|December 11, 2012
Dual Inhibition of Phosphatidylinositol 3-Kinase and Mammalian Target of Rapamycin: a Therapeutic Strategy for Acute LeukemiasF Chiarini, C Evangelisti, F Buontempo, et al.
Biochemical and Biophysical Research Communications|January 13, 2004
9-Hydroxystearic acid upregulates p21(WAF1) in HT29 cancer cellsN Calonghi, C Cappadone, E Pagnotta, et al.
Leukemia|July 28, 2016
Therapeutic potential of targeting sphingosine kinases and sphingosine 1-phosphate in hematological malignanciesC Evangelisti, C Evangelisti, F Buontempo, et al.
Leukemia|September 28, 2017
Therapeutic targeting of CK2 in acute and chronic leukemiasF Buontempo, J A McCubrey, E Orsini, et al.
Leukemia|December 7, 2013
Activity of the pan-class I phosphoinositide 3-kinase inhibitor NVP-BKM120 in T-cell acute lymphoblastic leukemiaA Lonetti, I L Antunes, F Chiarini, et al.
Leukemia|November 21, 2013
Cytotoxic activity of the casein kinase 2 inhibitor CX-4945 against T-cell acute lymphoblastic leukemia: targeting the unfolded protein response signalingF Buontempo, E Orsini, L R Martins, et al.
Pageof 1